Part D Brand Discounts May Be More Useful In Catastrophic Phase, House Panel Told

Medicare Payment Advisory Commission executive director Mathews suggests at April 30 hearing that manufacturers should bear more “liability” for catastrophic coverage in Medicare Part D.

pharmacist-discount-drugs

Manufacturer discounts on branded drugs provided to Medicare Part D beneficiaries in the coverage gap may be more helpful in lowering costs if they are required in the catastrophic phase of the benefit, Medicare Payment Advisory Commission executive director James Mathews told a US House subcommittee on 30 April.

MedPAC is interested in the idea of shifting the 70% discount requirement to the catastrophic phase but has not yet...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

Japan To Cut Leqembi Price By 15% Following Cost Effectiveness Review

 
• By 

While Japanese government announces 8-15% price cuts for four drugs, including Leqembi, industry groups urge operational improvements to national cost effectiveness assessment scheme.

BioMarin Fights Back After NICE Blocks English Funding For £500K Batten Disease Drug

 

The health technology assessment institute, NICE, said the price BioMarin was asking for Brineura was too high, even though its appraisal committee applied a cost-effectiveness threshold ten times higher than usual.

Dutch HTA Calls For “Socially Acceptable” Price For Gene Editing Therapy Casgevy

 

Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.

Lilly’s Price Deal For Mounjaro In UK A Harbinger Of The MFN Future?

 
• By 

The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.

More from Pink Sheet

Japan To Cut Leqembi Price By 15% Following Cost Effectiveness Review

 
• By 

While Japanese government announces 8-15% price cuts for four drugs, including Leqembi, industry groups urge operational improvements to national cost effectiveness assessment scheme.

Precigen’s Papzimeous Approval Allows US FDA CBER Director To Emphasize Flexibility

 

Returning FDA biologics center director Vinay Prasad used the Papzimeous approval announcement to reinforce his flexibility on rare disease therapies after several complete response letters and his brief departure from the agency.

Generic Drug Industry Seeks More US FDA Communication Reforms In GDUFA Renewal

 
• By 

Enhancing the consistency and clarity of information requests and discipline review letters, and improving assessment milestone communications are key areas targeted by generic drug makers for user fee program negotiations.